AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3877283 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg propofol
Number of subjects: 32
Study 3877283 — intervention group
Group type: COMPARATOR
Intervention: 0.05 ml/kg Althesin
Number of subjects: 32
Study 31319882 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal auto‐adjusting continuous positive airway pressure (APAP)
Number of subjects: 21
Study 31319882 — intervention group
Group type: COMPARATOR
Intervention: Nocturnal oxygen therapy (NOT)
Number of subjects: 21
Study 30407969 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimulation by a male nurse, recorded on MP3, administered twice a day for 10 days, repeated 3 to 4 times.
Number of subjects: 60
Study 30407969 — intervention group
Group type: COMPARATOR
Intervention: Control group (no auditory stimulation).
Number of subjects: 60
Study 27391818 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured multi‐component intervention (algorithm‐driven intervention using fixed‐dose combination antihypertensive treatment, subsidized FDC antihypertensive medication, motivational conversation, telephone follow‐ups)
Number of subjects: 100
Study 27391818 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 100
Study 27391818 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured multi‐component intervention
Number of subjects: 100
Study 27391818 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured multi‐component intervention and Usual care (control group)
Number of subjects: 100
Study 25444830 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine alone
Number of subjects: 129
Study 25444830 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine plus 10 μg dmLT
Number of subjects: 129
Study 25444830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 22406656 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus QD
Number of subjects: 34
Study 22406656 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus BID
Number of subjects: 34
Study 19786958 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbscan‐II
Number of subjects: 118
Study 19786958 — intervention group
Group type: COMPARATOR
Intervention: Topcon SP‐2000P
Number of subjects: 118
Study 19786958 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of devices
Number of subjects: 118
Study 17637782 — intervention group
Group type: EXPERIMENTAL
Intervention: Uracil‐Ftorafur (UFT)
Number of subjects: 0
Study 17637782 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronomodulated delivery schedules for floxuridine and FU infusions
Number of subjects: 0
Study 17637782 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronopharmacology of FU prodrugs
Number of subjects: 0
Study 15699445 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (ISMN)
Number of subjects: 16
Study 12523588 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d
Number of subjects: 197
Study 12523588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 10598761 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lactic acid
Number of subjects: 32
Study 10598761 — intervention group
Group type: COMPARATOR
Intervention: Pure water
Number of subjects: 32
Study 8619532 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma knife pallidotomy (180 Gy delivered in one sitting to the right posteroventral pallidum)
Number of subjects: 4
Study 1672578 — intervention group
Group type: COMPARATOR
Intervention: succinylcholine 2.0 mg/kg
Number of subjects: 40
Study 1672578 — intervention group
Group type: EXPERIMENTAL
Intervention: vecuronium 0.1 mg/kg
Number of subjects: 40
Study 1672578 — intervention group
Group type: EXPERIMENTAL
Intervention: vecuronium 0.2 mg/kg
Number of subjects: 40
Study 1672578 — intervention group
Group type: EXPERIMENTAL
Intervention: vecuronium 0.4 mg/kg
Number of subjects: 40
Study 7037034 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release aminophylline (Phyllocontin) 325 mg twice daily
Number of subjects: 20
Study 7037034 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release theophylline (Rona‐slophyllin) 250 mg twice daily
Number of subjects: 20
Study 7037034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7037034 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with plasma theophylline levels greater than 10 micrograms/ml
Number of subjects: 20
Study 31039724 — intervention group
Group type: EXPERIMENTAL
Intervention: Realistic patterns of species loss (community disassembly)
Number of subjects: 147
Study 31039724 — intervention group
Group type: COMPARATOR
Intervention: Randomized patterns of species loss
Number of subjects: 147
Study 28337838 — intervention group
Group type: EXPERIMENTAL
Intervention: mavoglurant 400 mg
Number of subjects: 30
Study 28337838 — intervention group
Group type: EXPERIMENTAL
Intervention: baclofen 40 mg
Number of subjects: 30
Study 28337838 — intervention group
Group type: COMPARATOR
Intervention: mavoglurant 50 mg
Number of subjects: 30
Study 26351530 — intervention group
Group type: EXPERIMENTAL
Intervention: ALAnerv® (2cps/day for 28 days)
Number of subjects: 59
Study 26351530 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59
Study 26351530 — intervention group
Group type: EXPERIMENTAL
Intervention: ALAnerv®
Number of subjects: 59
Study 22764199 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiting longer during the initial PVI procedure (wait group)
Number of subjects: 107
Study 22764199 — intervention group
Group type: COMPARATOR
Intervention: Immediate termination of the procedure after initial successful isolation (stop group)
Number of subjects: 107
Study 21360203 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance training (HI-RT, 75% of one repetition maximum [1-RM])
Number of subjects: 40
Study 21360203 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined HI-RT and low-intensity blood flow restriction training (CB-RT, twice-weekly LI-BFR and once-weekly HI-RT)
Number of subjects: 40
Study 21360203 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity resistance training with blood flow restriction (LI-BFR, 30% 1-RM)
Number of subjects: 40
Study 21360203 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance training (HI-RT)
Number of subjects: 40
Study 21360203 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined HI-RT and low-intensity blood flow restriction training (CB-RT)
Number of subjects: 40
Study 21360203 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity resistance training with blood flow restriction (LI-BFR)
Number of subjects: 40
Study 21360203 — intervention group
Group type: COMPARATOR
Intervention: Nontraining control (CON)
Number of subjects: 40
Study 19726310 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with laparoscopy, endoscopic and digital subtraction angiography in addition to conventional treatment (group B)
Number of subjects: 97
Study 19726310 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (group A)
Number of subjects: 97
Study 16780265 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine treatment
Number of subjects: 42
Study 16780265 — intervention group
Group type: COMPARATOR
Intervention: Control group (different drugs)
Number of subjects: 42
Study 15496643 — intervention group
Group type: EXPERIMENTAL
Intervention: desloratadine 5 mg plus fluoxetine 20 mg
Number of subjects: 54
Study 15496643 — intervention group
Group type: EXPERIMENTAL
Intervention: fluoxetine 20 mg plus desloratadine 5 mg
Number of subjects: 54
Study 15496643 — intervention group
Group type: COMPARATOR
Intervention: desloratadine 5 mg plus placebo
Number of subjects: 54
Study 15496643 — intervention group
Group type: COMPARATOR
Intervention: fluoxetine 20 mg plus placebo
Number of subjects: 54
Study 11206942 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid (tape and workbook)
Number of subjects: 0
Study 11206942 — intervention group
Group type: COMPARATOR
Intervention: Control pamphlet
Number of subjects: 0
Study 9438485 — intervention group
Group type: EXPERIMENTAL
Intervention: QID dosing of inhaled corticosteroids
Number of subjects: 3
Study 9438485 — intervention group
Group type: EXPERIMENTAL
Intervention: 5:30 PM dosing of inhaled corticosteroids
Number of subjects: 3
Study 9438485 — intervention group
Group type: COMPARATOR
Intervention: 8 AM dosing of inhaled corticosteroids
Number of subjects: 3
Study 8102538 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (n = 9)
Number of subjects: 17
Study 8102538 — intervention group
Group type: COMPARATOR
Intervention: Saline alone (n = 8)
Number of subjects: 17
Study 3315768 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture I (24.5 +/- 1.7 I.U. of isophane protamine insulin + 9.8 +/- 0.78 I.U. of short‐acting soluble insulin)
Number of subjects: 12
Study 3315768 — intervention group
Group type: COMPARATOR
Intervention: Mixture II (identical doses of insulin zinc suspension + soluble insulin)
Number of subjects: 12
Study 31237805 — intervention group
Group type: EXPERIMENTAL
Intervention: PSYCHLOPS Questionnaire
Number of subjects: 867
Study 31237805 — intervention group
Group type: COMPARATOR
Intervention: Conventional, nomothetic measures
Number of subjects: 867
Study 29563133 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational physical activity at least several times a month
Number of subjects: 1992
Study 29563133 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 1992
Study 29122264 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing techniques training
Number of subjects: 70
Study 29122264 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study 26199083 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency 'inhibiting' off-line repetitive transcranial magnetic stimulation (rTMS) on the left dorsal prefrontal cortex
Number of subjects: 0
Study 26199083 — intervention group
Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 0
Study 24159259 — intervention group
Group type: EXPERIMENTAL
Intervention: QVA149 (110 μg indacaterol/50 μg glycopyrronium)
Number of subjects: 193
Study 24159259 — intervention group
Group type: COMPARATOR
Intervention: IND+GLY (150 μg indacaterol and 50 μg glycopyrronium)
Number of subjects: 193
Study 24159259 — intervention group
Group type: EXPERIMENTAL
Intervention: QVA149
Number of subjects: 193
Study 24159259 — intervention group
Group type: COMPARATOR
Intervention: IND+GLY
Number of subjects: 193
Study 21145201 — intervention group
Group type: EXPERIMENTAL
Intervention: History of depression or active depressive symptoms
Number of subjects: 376
Study 21145201 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferences for mechanical ventilation (MV)
Number of subjects: 376
Study 21145201 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferences for cardiopulmonary resuscitation (CPR)
Number of subjects: 376
Study 17987059 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment with BDNF Val66Met polymorphism
Number of subjects: 196
Study 17987059 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 196
Study 17987059 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 196
Study 16510466 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg t.i.d.)
Number of subjects: 12
Study 16510466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15107368 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy (active mobilisation)
Number of subjects: 200
Study 15107368 — intervention group
Group type: COMPARATOR
Intervention: Collar therapy (cervical orthosis)
Number of subjects: 200
Study 11454106 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 1 mg bid
Number of subjects: 177
Study 11454106 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg bid
Number of subjects: 177
Study 11454106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 9735623 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical treatment with taping and orthoses
Number of subjects: 103
Study 9735623 — intervention group
Group type: COMPARATOR
Intervention: Anti-inflammatory treatment
Number of subjects: 103
Study 9735623 — intervention group
Group type: COMPARATOR
Intervention: Accommodative treatment
Number of subjects: 103
Study 7986837 — intervention group
Group type: COMPARATOR
Intervention: Conventional CT technique, CM volume 150 ml of Ultravist 300 (30 ml at a flow rate of 1.5 ml/s, remaining 120 ml at 0.5 ml/s)
Number of subjects: 60
Study 7986837 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic CT technique, CM volume 100 ml (200 ml at a flow rate of 2 ml/s and 80 ml at 0.5 ml/s)
Number of subjects: 60
Study 7986837 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral CT technique, CM dosage of 50 ml (30 ml at a flow rate of 2 ml/s and 20 ml at 0.7 ml/s)
Number of subjects: 60
Study 3281618 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of atenolol
Number of subjects: 27
Study 3281618 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of metoprolol tartrate
Number of subjects: 27
Study 3281618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 31352829 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose edoxaban regimen (60/30 mg)
Number of subjects: 19679
Study 31352829 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 19679
Study 28501319 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary 3‐phenoxybenzoic acid (3‐PBA) levels
Number of subjects: 305
Study 25640526 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive remediation (COG REM) with social skills training (SST) for 6 months
Number of subjects: 64
Study 25640526 — intervention group
Group type: COMPARATOR
Intervention: Computer skills training with social skills training (SST)
Number of subjects: 64
Study 23809273 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereoscopic optic disc photographs
Number of subjects: 109
Study 23809273 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver agreement
Number of subjects: 109
Study 21612945 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate cloths
Number of subjects: 100
Study 21612945 — intervention group
Group type: COMPARATOR
Intervention: Shower with soap and water
Number of subjects: 100
Study 18028460 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic drink containing Lactobacillus paracasei Lpc‐37, Lactobacillus acidophilus 74‐2, and Bifidobacterium animalis subsp. lactis DGCC 420
Number of subjects: 30
Study 18028460 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic drink
Number of subjects: 30
Study 18028460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16530506 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback (5 weekly sessions)
Number of subjects: 109
Study 16530506 — intervention group
Group type: COMPARATOR
Intervention: Laxatives (polyethylene glycol 14.6‐29.2 g/day plus 5 weekly counseling sessions)
Number of subjects: 109
Study 12716519 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 150
Study 12716519 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive method of comprehensive factors
Number of subjects: 150
Study 10657405 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 126
Study 10657405 — intervention group
Group type: COMPARATOR
Intervention: Control group (antithrombotic treatment)
Number of subjects: 126
Study 9301505 — intervention group
Group type: COMPARATOR
Intervention: Control (diet < 25% energy as fat)
Number of subjects: 20
Study 9301505 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran (25 g/day)
Number of subjects: 20
Study 9301505 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat bran (64 g/day)
Number of subjects: 20
Study 9301505 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed wheat bran (Kellogg's All Bran, 38 g/day)
Number of subjects: 20
Study 8326670 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 gauge spinal needle
Number of subjects: 125
Study 8326670 — intervention group
Group type: EXPERIMENTAL
Intervention: 22 gauge spinal needle
Number of subjects: 125
Study 8326670 — intervention group
Group type: EXPERIMENTAL
Intervention: 23 gauge spinal needle
Number of subjects: 125
Study 8326670 — intervention group
Group type: COMPARATOR
Intervention: 24 gauge spinal needle
Number of subjects: 125
Study 8326670 — intervention group
Group type: COMPARATOR
Intervention: 25 gauge spinal needle
Number of subjects: 125
Study 3548611 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem (500 mg t.i.d.)
Number of subjects: 93
Study 3548611 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin plus Clindamycin (600 mg t.i.d.)
Number of subjects: 93
Study 3548611 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 93
Study 3548611 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin plus Clindamycin
Number of subjects: 93
Study 30239215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascending silhouette ordering
Number of subjects: 153
Study 30239215 — intervention group
Group type: COMPARATOR
Intervention: Randomized figure ordering
Number of subjects: 153
Study 30332312 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 474
Study 30332312 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support among YBMSM living with HIV
Number of subjects: 474
Study 30332312 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigma
Number of subjects: 474
Study 27581113 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-temperature atmospheric-pressure plasma (LTAPP) once every week for 8 consecutive weeks in addition to standard wound care
Number of subjects: 50
Study 27581113 — intervention group
Group type: COMPARATOR
Intervention: Standard wound care
Number of subjects: 50
Study 27581113 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-temperature atmospheric-pressure plasma (LTAPP)
Number of subjects: 50
Study 24178405 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational conjunctival flap with adjunctive subconjunctival 2.5 mg/0.1 ml bevacizumab injection (Group C)
Number of subjects: 90
Study 24178405 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational conjunctival flap with 0.02% mitomycin C application (Group B)
Number of subjects: 90
Study 24178405 — intervention group
Group type: COMPARATOR
Intervention: Rotational conjunctival flap alone (Group A)
Number of subjects: 90
Study 23327586 — intervention group
Group type: EXPERIMENTAL
Intervention: M-0.2% CHX-diurnal (mouthrinse at 7:00 am)
Number of subjects: 10
Study 23327586 — intervention group
Group type: EXPERIMENTAL
Intervention: M-0.2% CHX-nocturnal (mouthrinse at 1:00 am)
Number of subjects: 10
Study 20862715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Salvia miltiorrhiza after surgery for 3 days
Number of subjects: 90
Study 20862715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anisodamine after surgery for 3 days
Number of subjects: 90
Study 20862715 — intervention group
Group type: COMPARATOR
Intervention: Routine wound care (Control group 1)
Number of subjects: 90
Study 18606053 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin sulfate 7500 IU/neomycin sulfate 3500 IU/dexamethasone phosphate 0.1% (PN+Dx)
Number of subjects: 338
Study 18606053 — intervention group
Group type: COMPARATOR
Intervention: Polymyxin sulfate 7500 IU/neomycin sulfate 3500 IU (PN‐Dx)
Number of subjects: 338
Study 15705013 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 125
Study 15705013 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine
Number of subjects: 125
Study 15705013 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 125
Study 15705013 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 125
Study 15705013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 15705013 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medication (stimulant and nonstimulant combined)
Number of subjects: 125
Study 12546641 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin, Simvastatin, Pravastatin
Number of subjects: 75
Study 12546641 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 75
Study 10844830 — intervention group
Group type: EXPERIMENTAL
Intervention: High inspired oxygen fraction (FIO2) after CPB (FIO2 of 1.0, exposure time 70 min)
Number of subjects: 20
Study 10844830 — intervention group
Group type: COMPARATOR
Intervention: Moderate inspired oxygen fraction (FIO2) after CPB (FIO2 of 0.35)
Number of subjects: 20
Study 10844830 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of FIO2 from 1.0 to 0.6
Number of subjects: 20
Study 10844830 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative day 1 measurements
Number of subjects: 20
Study 8872838 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness intervention
Number of subjects: 1147
Study 8872838 — intervention group
Group type: EXPERIMENTAL
Intervention: Home nutrition intervention
Number of subjects: 1147
Study 8872838 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness programme
Number of subjects: 1147
Study 8872838 — intervention group
Group type: EXPERIMENTAL
Intervention: Home nutrition programmes
Number of subjects: 1147
Study 8872838 — intervention group
Group type: COMPARATOR
Intervention: School + home nutrition intervention
Number of subjects: 1147
Study 1814603 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine infusion at 6.25 mg/hr
Number of subjects: 12
Study 1814603 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine infusion at 10.0 mg/hr
Number of subjects: 12
Study 1814603 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine infusion (6.25 mg/hr and 10.0 mg/hr)
Number of subjects: 12
Study 1814603 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine infusion
Number of subjects: 12
Study 6370586 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-GA Cu
Number of subjects: 200
Study 6370586 — intervention group
Group type: COMPARATOR
Intervention: Copper-T
Number of subjects: 200
Study 29804469 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc Gluconate 233 mg/day plus vitamin E 400 IU/day for 6 weeks
Number of subjects: 54
Study 29804469 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 54